IRD
Opus Genetics, Inc. Common Stock
About: Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.
Employees: 18
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
650% more call options, than puts
Call options by funds: $15K | Put options by funds: $2K
100% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 6
63% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 8
32% more capital invested
Capital invested by funds: $3.32M [Q3] → $4.37M (+$1.05M) [Q4]
11% more funds holding
Funds holding: 38 [Q3] → 42 (+4) [Q4]
1.96% more ownership
Funds ownership: 9.66% [Q3] → 11.62% (+1.96%) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$6
544%
upside
Avg. target
$7.33
687%
upside
High target
$8
758%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Craig-Hallum Albert Lowe 43% 1-year accuracy 3 / 7 met price target | 544%upside $6 | Buy Initiated | 11 Apr 2025 |
Jones Trading | 758%upside $8 | Buy Maintained | 1 Apr 2025 |
HC Wainwright & Co. Matthew Caufield 36% 1-year accuracy 24 / 67 met price target | 758%upside $8 | Buy Reiterated | 1 Apr 2025 |
Financial journalist opinion
Based on 5 articles about IRD published over the past 30 days
Neutral
GlobeNewsWire
17 hours ago
Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate
RESEARCH TRIANGLE PARK, N.C., May 06, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other ophthalmic disorders, announced today that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to OPGx-LCA5, its investigational gene therapy for the treatment of Leber Congenital Amaurosis (LCA) due to genetic variations in the LCA5 gene.
Neutral
GlobeNewsWire
1 day ago
Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision
Improvements in subjective and objective measures of efficacy observed at six months persisted for one year in patients with severe vision impairment from inherited retinal degeneration due to mutations in the LCA5 gene
Negative
Zacks Investment Research
4 days ago
Earnings Preview: Opus Genetics, Inc. (IRD) Q1 Earnings Expected to Decline
Opus Genetics, Inc. (IRD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neutral
GlobeNewsWire
3 weeks ago
Founder Mina Sooch Issues Open Letter to Opus Genetics Stockholders Following Withdrawal of the Restore Value Slate Amid Dilutive Financing and Governance Concerns
Board Timed Highly Dilutive Financing to Close on the Record Date for the Annual Meeting, Tilting the Vote and Forcing the Withdrawal of the Restore Value Slate
Neutral
GlobeNewsWire
4 weeks ago
Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases
First pediatric patient shows encouraging early safety profile and meaningful improvement in visual function at one month A second pediatric patient was recently dosed, and the pediatric cohort is expected to complete enrollment in Q2 2025; initial data from all three patients anticipated in Q3 2025 FDA Type D meeting provided clarity on next steps for a registrational trial design to support BLA submission, with potential trial initiation in 2026 DURHAM, N.C., April 08, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and to treat other ophthalmic disorders (“Opus” or the “Company”), today announced one-month clinical data from the first pediatric patient treated with its investigational gene therapy, OPGx-LCA5, in a Phase 1/2 open-label trial for LCA5-related inherited retinal disease (IRD).
Neutral
GlobeNewsWire
1 month ago
Opus Genetics to Participate in Upcoming Investor Conference in April
RESEARCH TRIANGLE PARK, N.C., April 02, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and therapies for other ophthalmic disorders, today announced that George Magrath, M.D.
Neutral
GlobeNewsWire
1 month ago
Opus Genetics Announces Financial Results for Full Year 2024
Provides update on the Company's transformation and promising portfolio of innovative gene therapy treatments for inherited retinal diseases
Neutral
GlobeNewsWire
1 month ago
Restore Value Slate Led by Mina Sooch Files Preliminary Proxy Materials for the Election of Six Highly Qualified Directors at the 2025 Annual Meeting of Opus Genetics
Believes that Current Board's Strategic, Management and Capital Allocation Failures have Resulted in Stockholder Value Destruction
Neutral
GlobeNewsWire
1 month ago
Opus Genetics Announces Presentation on Phentolamine Ophthalmic Solution 0.75% in Dim Light Disturbances at World Cornea Congress IX
RESEARCH TRIANGLE PARK, N.C., March 21, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and therapies for other ophthalmic disorders, today announced that a presentation featuring the LYNX-1 Phase 3 study of Phentolamine Ophthalmic Solution 0.75% in patients with dim light disturbances will be delivered this week at World Cornea Congress IX, taking place March 20-22, 2025 in Washington, D.C.
Neutral
GlobeNewsWire
1 month ago
Opus Genetics Announces Pricing of Public Offering and Concurrent Private Placement with Proceeds of Over $20 Million
Additional approximately $21 million tied to data release for the Company's BEST1 program Additional approximately $21 million tied to data release for the Company's BEST1 program
Charts implemented using Lightweight Charts™